Illustrative image – not actual.
Maiva Pharma has raised Rs 1,000 crore from Morgan Stanley Private Equity Asia and India Life Sciences Fund, including both primary and secondary funding. The funds will be used to set up a new manufacturing facility near Hosur in Karnataka, with capabilities in sterile dosage forms, including pre-filled syringes, bags, oncology, and hormonal injectables.
This fundraise, which is Maiva's first private equity fundraise will be utilised to add more vial, lyophilisation, and suspension capacity, and provide new manufacturing capabilities such as prefilled syringes, cartridges and bags. The two investors have jointly acquired a controlling stake and also infused primary capital into the company. The firm already has a facility in Hosur approved by the USFDA for manufacturing of vials.
Avendus acted as the exclusive financial advisor to Maiva on the deal.
Maiva's complex injectables development and manufacturing capability, strong compliance and regulatory standards are its differentiators.The company is poised to partake of the injectables CDMO market which is poised for strong growth.
